From Cholesterol Control to Critical Illness: A Case of Statin-Associated Rhabdomyolysis With Concurrent Acute Kidney Injury and Hepatotoxicity

Statins, or HMG-CoA reductase inhibitors, are among the most commonly prescribed medications globally due to their well-established efficacy in lowering low-density lipoprotein cholesterol (LDL-C) and reducing the risk of atherosclerotic cardiovascular disease. Their widespread use in both primary and secondary prevention strategies has significantly contributed to declines in cardiovascular morbidity and mortality. Despite their favorable safety profile, statins are not without risk. Rare but potentially life-threatening complications such as rhabdomyolysis, hepatotoxicity, and acute kidney injury (AKI) can occur, particularly in individuals with specific risk factors, such as advanced age, renal impairment, high-dose therapy, or concurrent use of drugs that alter statin metabolism. Understanding the spectrum and mechanisms of these adverse effects is essential for prompt identification and management to prevent serious outcomes.